Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.57 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14478293 | 1.00 | SLC6A4 (0.58) | SLC6A4TP53TSHRTAAR1SLC6A2 | |
| SCHEMBL9292319 | 1.00 | SLC6A4 (0.58) | SLC6A4TP53TSHRTAAR1SLC6A2 | |
| SCHEMBL10872752 | 0.83 | TAAR1 (0.76) | SLC6A4TAAR1SLC6A2SLC6A3MAOA | |
| SCHEMBL17504541 | 0.83 | TP53 (0.55) | SLC6A4TP53TSHRTAAR1SIGMAR1 | |
| SCHEMBL8671989 | 0.83 | SLC6A4 (0.55) | SLC6A4TAAR1SLC6A2SLC6A3MAOA | |
| SCHEMBL10872755 | 0.83 | TAAR1 (0.76) | SLC6A4TAAR1SLC6A2SLC6A3MAOA | |
| SCHEMBL547420 | 0.82 | TSHR (0.62) | TP53TSHRSIGMAR1 | |
| SCHEMBL23986815 | 0.82 | TP53 (0.53) | SLC6A4TP53TSHRSIGMAR1 | |
| SCHEMBL3813110 | 0.81 | HTR2A (0.65) | SLC6A4TAAR1SLC6A2SLC6A3MAOA | |
| SCHEMBL265675 | 0.81 | HTR2A (0.65) | SLC6A4TAAR1SLC6A2SLC6A3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361648-B2 | Heterocyclylakylamines as muscarinic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2008-04-22 | — | — | US | disclosed |
| US-20060287293-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | ROCHE PALO ALTO LLC | 2006-12-21 | — | — | US | disclosed |
| US-7094778-B2 | Heterocyclylalkylamines as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1289965-B1 | SUBSTITUTED 1-AMINOALKYL-LACTAMS AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-10-26 | — | — | EP | disclosed |
| CN-1178922-C | Substituted 1-aminoalkyllactam compounds and their use as muscarinic receptor antagonists | - | 2004-12-08 | — | — | CN | disclosed |
| US-20040087581-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | DVORAK CHARLES ALOIS (US) | 2004-05-06 | — | — | US | disclosed |
| US-6667301-B2 | Therapy for muscular disorders, urogenital disorders, gastrointestinal disorders, respiratory system disorders | SYNTEX (U.S.A.) LLC | 2003-12-23 | — | — | US | disclosed |
| CN-1430610-A | Substituted 1-aminoalkyllactam compounds and their use as muscarinic receptor antagonists | HOFFMANN LA ROCHE (CH) | 2003-07-16 | — | — | CN | disclosed |
| US-20020004501-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC | 2002-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287293-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM3 | SLC6A4 990/4885TP53 2501/4885TSHR 146/4885 |
| US-20020004501-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM1 | SLC6A4 880/4885TP53 2540/4885TSHR 120/4885 |
| US-20040087581-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM1 | SLC6A4 880/4885TP53 2540/4885TSHR 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.